CD47 and myeloid sarcoma: Both miRNA-146a (see above) and/or miRNA-155: (i) target the CD47 3′-UTR, promoting down-regulation of CD47 on brain resident cells, triggering the macrophage-mediated phagocytosis of myelin (Junker et al., 2009) and/or (ii) induce the development of IFN-γ-producing T helper type 1 (Th1) cell subsets and CD4(+) T cells that secrete interleukin (IL)-17 (Th17 cells); these cells are known to induce inflammatory degeneration in MS, psoriasis, autoimmune uveitis and rheumatoid arthritis (Ma et al., 2014; Seddiki et al., 2014; Stürner et al., 2014).